A randomized prospective controlled trial of long-acting muscarinic antagonist and long-acting be-ta2 agonist fixed dose combinations in patients with chronic obstructive pulmonary disease: Effects on quality of life and pulmonary function and preference

AA randomized prospective controlled trial of long-acting muscarinic antagonist and long-acting be-ta2 agonist fixed dose combinations in patients with chronic obstructive pulmonary disease: Effects on quality of life and pulmonary function and preference - A randomized prospective controlled trial of long-acting muscarinic antagonist and long-acting be-ta2 agonist fixed dose combinations in patients with chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041342

Enrollment

100

Registered

2020-08-06

Start date

2017-01-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

glycopyrronium/ indacaterol (Gly/ Ind

Ultibro), once daily for 4 weeks umeclidinium/ vilanterol (Ume/ Vil

Anoro), once daily for 4 weeks tiotropium/ olodaterol (Tio/ Olo

Spiorto), once daily for 4 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: COPD patients obtained informed consent

Exclusion criteria

Exclusion criteria: Inability to inhale unassisted; inability to perform spirometry tests; pregnancy; severe comorbidities affecting quality of life, including malignancy, cardiac failure, renal failure, or severe liver dysfunction; and comorbidity of severe prostatic hypertrophy and closed-angle glaucoma.

Design outcomes

Primary

Measure	Time frame
Differences in preference, QoL, respiratory function, and adverse events among three medications	—

Secondary

Measure	Time frame
The relationship between the medication selected as the first rank in the final comparative questionnaire and the background factors of the patients	—

Countries

Japan

Contacts

Public ContactMasato Muraki

Kindai University Nara Hospital Department of Respiratory Medicine and Allergology

muraki-m@med.kindai.ac.jp0743-77-0880

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026